Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

for
Recurrent Endometrial Carcinoma,
Location: Providence RI, Philadelphia PA, Augusta GA,
Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05950464

Phase 1, Recruiting

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

for
Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer,
Location: Chicago IL
Sponsor: Northwestern University

Sex: Female

Age: 18 - 70+

Code: NCT00005095

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

for
High-grade Serous Ovarian Carcinoma (HGSOC),
Location: Hackensack NJ, Montreal, Toronto, Vancouver,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT06476808

Phase 1, Recruiting

Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer

for
Ovarian Cancer, Stage III Ovarian Cancer,
Location: Toronto
Sponsor: Sunnybrook Health Sciences Centre

Sex: Female

Age: 18+

Code: NCT05961124

Phase 2, Recruiting

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for
High Grade Epithelial Ovarian Cancer,
Location: Boston MA, Providence RI, Camden NJ, Doylestown PA,
Sponsor: Genmab

Sex: All

Age: 18+

Code: NCT05579366

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

for
Ovarian Clear Cell Adenocarcinoma,
Location: Buffalo NY, Houston TX
Sponsor: Roswell Park Cancer Institute

Sex: Female

Age: 18+

Code: NCT05231122

Phase 2, Recruiting

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

for
Advanced Ovarian Carcinoma,
Location: Boston MA, Mineola NY, New York NY, Bethlehem PA,
Sponsor: M.D. Anderson Cancer Center

Sex: Female

Age: 18+

Code: NCT04575935

Phase 3, Recruiting

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

for
Ovarian Neoplasms, Ovarian Epithelial Carcinoma,
Location: Boston MA, Annapolis MD, Baltimore MD, Little Rock AR,
Sponsor: Massachusetts General Hospital

Sex: Female

Age: 30+

Code: NCT04794322

Recruiting

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

for
Advanced Fallopian Tube Carcinoma,
Location: Jacksonville FL, Rochester MN, Scottsdale AZ
Sponsor: Mayo Clinic

Sex: Female

Age: 18+

Code: NCT06639074

Phase 2, Recruiting

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

for
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma,
Location: Long Branch NJ, Toms River NJ, New Brunswick NJ,
Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT07504588

Phase 2, Recruiting

Uterine Lavage to Detect Ovarian Cancer Risk

for
BRCA Hereditary Ovarian Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: Female

Age: 18+

Code: NCT07772869

Recruiting

A Study of Isoquercetin in People With Ovarian Cancer

for
Ovarian Cancer, Epithelial Ovarian Cancer, Serous Ovarian Tumor
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07303894

Phase 2, Recruiting

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

for
Epithelial Ovarian Cancer, Ovarian Cancer,
Location: Rochester NY, Orlando FL, Detroit MI, Chattanooga TN,
Sponsor: Imunon

Sex: Female

Age: 18+

Code: NCT06915025

Phase 3, Recruiting

Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients

for
Ovarian Cancer, Epithelial Ovarian Cancer,
Location: Kansas City KS
Sponsor: Andrea Jewell

Sex: Female

Age: 18+

Code: NCT03321188

Phase 2, Recruiting

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for
Fallopian Tube Endometrioid Adenocarcinoma,
Location: Scarborough ME, Providence RI, Commack NY, Norwalk CT,
Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06580314

Phase 3, Recruiting
New

Ovarian Cancer Liquid Biopsy for Early Assessment & Detection in Individuals With BRCA1/2 Pathogenic Variants

for
Ovarian Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation,
Location: New York NY
Sponsor: Weill Medical College of Cornell University

Sex: Female

Age: 35+

Code: NCT07764744

Recruiting
New

Mo-Rez in First- Line (1L) Maintenance Treatment of Non-Homologous Recombination Deficient Ovarian Cancer (Non-HRd OC) [BEHOLD-Ovarian03]

for
Ovarian Neoplasms
Location: Montreal, Toronto
Sponsor: GlaxoSmithKline

Sex: Female

Age: 18+

Code: NCT07694427

Phase 3, Recruiting
New

CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

for
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M),
Location: Fairfax VA, Dallas TX, Austin TX
Sponsor: Crescent Biopharma, Inc.

Sex: All

Age: 18+

Code: NCT07909031

Phase 1, Phase 2, Recruiting
New

A Study to Evaluate OPB-201 in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

for
Endometrial Cancer Recurrent, Endometrial Cancer,
Location: Detroit MI, Atlanta GA, Minneapolis MN, Houston TX,
Sponsor: Outpace Bio, Inc.

Sex: Female

Age: 18+

Code: NCT07664735

Phase 1, Recruiting
New

A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

for
Ovarian Cancer
Location: Lake Success NY, Philadelphia PA, Fairfax VA,
Sponsor: Phrontline Biopharma

Sex: All

Age: 18+

Code: NCT07778498

Phase 1, Phase 2, Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial